Alector, Inc.

$2.12+0.47%(+$0.01)
TickerSpark Score
45/100
Weak
45
Valuation
40
Profitability
10
Growth
68
Health
60
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALEC research report →

52-Week Range45% of range
Low $1.09
Current $2.12
High $3.40

Companywww.alector.com

Alector, Inc. , a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

CEO
Arnon Rosenthal
IPO
2019
Employees
175
HQ
South San Francisco, CA, US

Price Chart

+54.74% · this period
$3.32$2.23$1.14May 20Nov 18May 20

Valuation

Market Cap
$235.37M
P/E
-1.87
P/S
12.78
P/B
22.58
EV/EBITDA
-1.55
Div Yield
0.00%

Profitability

Gross Margin
88.68%
Op Margin
-741.33%
Net Margin
-680.83%
ROE
-295.17%
ROIC
-65.15%

Growth & Income

Revenue
$21.05M · -79.07%
Net Income
$-142,929,000 · -20.06%
EPS
$-1.39 · -13.01%
Op Income
$-145,807,000
FCF YoY
20.37%

Performance & Tape

52W High
$3.40
52W Low
$1.09
50D MA
$2.31
200D MA
$2.10
Beta
0.65
Avg Volume
708.45K

Get TickerSpark's AI analysis on ALEC

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Apr 16, 26Wong-Sarad Gracesell1,820
Mar 13, 26Rosenthal Arnonother116,246
Mar 15, 26Berkley Neil Lindsayother54,600
Mar 10, 26Wong-Sarad Gracesell1,000
Mar 3, 26Wong-Sarad Gracesell3,367
Mar 2, 26Wong-Sarad Gracesell8,071
Mar 2, 26Rosenthal Arnonsell81,864
Mar 2, 26Berkley Neil Lindsaysell29,649
Feb 26, 26Wong-Sarad Gracesell4,079
Dec 5, 25Wong-Sarad Gracesell4,753

Our ALEC Coverage

We haven't published any research on ALEC yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate ALEC Report →

Similar Companies